A method for preparing F genotype mumps live attenuated vaccine by culturing human diploid cells on a large scale

By using sheet-like vectors and optimized parameters to cultivate human diploid cells in a fixed bed bioreactor, the scale and safety issues of live mumps attenuated vaccine production are solved, and efficient and low-cost F-genotype parotid glands are achieved. The production of inflammatory virus vaccines replaces the traditional cell factory model.

CN116574693BActive Publication Date: 2024-11-15INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202310530682.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-05-11
Publication Date
2024-11-15
Estimated Expiration
2043-05-11

AI Technical Summary

Technical Problem

The existing technology is difficult to achieve the production of large-scale, safe and economical live mumps attenuated vaccines, especially the cultivation of F genotype mumps virus.

Method used

Using fixed bed bioreactor and sheet-like vector as adherent media, human diploid cells were cultured on a large scale, F genotype mumps virus strains were inoculated, and virus culture was carried out using optimized culture parameters, and finally obtained by filtration and lyophilization. Vaccine stock solution and finished products.

Benefits of technology

It has achieved large-scale production of mumps virus, with large output, low cost and stable quality, replacing the traditional cell factory culture model and providing a safer and more effective live mumps attenuated vaccine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116574693B_ABST
    Figure CN116574693B_ABST
Patent Text Reader

Abstract

The present invention relates to the technical field of vaccine preparation, and in particular to a method for mass culturing human diploid cells to produce a live attenuated mumps vaccine. The present invention provides a method for mass culturing human diploid cells to produce a live attenuated mumps vaccine, comprising the following steps: (1) inoculating human diploid cells into a bioreactor for culturing; (2) inoculating the bioreactor with mumps virus and continuing to culture; (3) preparing a harvest solution; (4) preparing a stock solution of the vaccine; (5) preparing a semi-finished vaccine product; and (6) preparing a finished vaccine product. The present invention utilizes a fixed-bed bioreactor to replace a traditional cell factory, and can realize the mass culturing of human diploid cells to produce a live attenuated mumps vaccine using a bioreactor.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of vaccine preparation, and in particular to a method for preparing a live attenuated F genotype mumps vaccine by culturing human diploid cells on a large scale. Background Art

[0002] Mumps is an acute respiratory infectious disease caused by mumps virus infection, which is transmitted through the air and mainly occurs in children and adolescents. Mumps has a high incidence rate and is highly contagious. Its complications can infect the central nervous system and cause death. Since the 1960s, with the widespread use of mumps live attenuated vaccines, mumps infection has been effectively controlled. Mumps virus is divided into 12 genotypes, and the distribution of mumps virus genotypes has obvious regionality. The main epidemic strains in Europe are A, C, D, G, and H, the main epidemic strains in the Americas are C, D, D, G, H, J, and K, and the main epidemic strains in Asia are B, F, I, and L. The current main epidemic strain is the F genotype. At present, the attenuated live vaccines being used worldwide are mainly A genes. The present invention is to prepare a mumps live attenuated vaccine by inoculating the F genotype mumps virus species SP-A strain independently screened and separated by our institute into human diploid cells, which is safer and more effective than the mumps vaccine currently on the market.

[0003] In recent years, with the increasing market demand for vaccines and therapeutic protein biological products and strict requirements for product quality, the application of large-scale cell culture technology has highlighted its safety, economy and effectiveness. The F genotype mumps attenuated virus strain SP-A has a certain sensitivity to the KMB-17 cell line, so the KMB-17 cell line can be used as a cell matrix for the production of mumps attenuated live vaccine. Because KMB-17 is an adhesion-dependent cell and grows slowly, the fixed bed bioreactor is used, and the sheet carrier is used as the adhesion medium to provide the best cell culture conditions, and a suitable large-scale culture system can be established to achieve high-density cell culture and efficient product expression.

[0004] Therefore, using a fixed-bed bioreactor to culture human diploid cells to produce a live attenuated mumps vaccine is an urgent problem to be solved by those skilled in the art. Summary of the invention

[0005] The purpose of the present invention is to provide a method for large-scale cultivation of human diploid cells to produce live attenuated mumps vaccine, which utilizes a fixed bed bioreactor to replace the traditional cell factory to cultivate human diploid cells on a large scale to produce live attenuated mumps vaccine.

[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0007] The present invention provides a method for producing a live attenuated mumps vaccine by culturing human diploid cells on a large scale, comprising the following steps:

[0008] (1) Human diploid cells were inoculated into a bioreactor for cell culture; the culture parameters of the bioreactor were set to pH 7.2, DO 50%, rotation speed 40 rpm, and temperature 37.0°C. After the bioreactor parameters were stable, the cells were inoculated into the reactor. The inoculation density was 2-3×10 5 / mL, the culture volume is 5 L. The cell culture time is 4 to 6 days.

[0009] (2) inoculating the mumps virus strain into the bioreactor and then culturing the virus; setting the culture parameters of the bioreactor to pH 7.8, DO 50%, rotation speed 40 rpm, and temperature 37.0° C., and after the bioreactor parameters are stable, inoculating the F genotype mumps virus seed at an MOI of 0.03, and culturing the virus for 10 days. Sampling is performed every day to detect the virus titer.

[0010] (3) After the virus culture is completed, collect the supernatant as the virus harvest fluid.

[0011] (4) The virus harvested fluid is filtered to obtain the vaccine stock solution.

[0012] (5) Add an equal volume of freeze-dried stabilizer to the vaccine stock solution to obtain a semi-finished product.

[0013] (6) The obtained vaccine semi-finished product is packaged into vials at a volume of 0.6 ml / bottle and freeze-dried to obtain the finished product.

[0014] Compared with the prior art, the present invention has the following beneficial effects:

[0015] (1) The present invention provides optimal culture conditions by using sheet carriers as adherent media in a fixed bed bioreactor, thereby enabling large-scale production of mumps virus.

[0016] (2) The present invention has the advantages of large output, low cost, stable quality, etc., and can produce a large amount of mumps virus live vaccine in a short time, which can replace the culture mode of traditional cell factory. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.

[0018] Figure 1It is the virus titer of F genotype mumps virus culture process (batch 202201 is an example, and batch 202202 and 202203 are comparative examples). DETAILED DESCRIPTION

[0019] The present invention provides a method for producing a live attenuated mumps vaccine by culturing human diploid cells on a large scale, comprising the following steps:

[0020] (1) Human diploid cells were inoculated into a bioreactor for cell culture; the culture parameters of the bioreactor were set to pH 7.2, DO 50%, rotation speed 40 rpm, and temperature 37.0°C. After the bioreactor parameters were stable, the cells were inoculated into the reactor. The inoculation density was 2-3×10 5 / mL, preferably 2.5×10 5 The cell culture time is 4 to 6 days, preferably 5 days.

[0021] (2) inoculating the adenovirus strain into the bioreactor and then culturing the virus; when the cell culture is completed, the cell mass reaches 35-50×10 8 The cell number is preferably not less than 40×10 8 The virus is cultured. The MOI of the adenovirus strain is 0.005-0.03; preferably, the MOI is 0.01 and the virus amount is calculated for inoculation and culture. The culture time is 10 days, preferably 5-6 days.

[0022] (3) After the virus culture is completed, collect the supernatant as the virus harvest fluid.

[0023] (4) The virus harvest solution is filtered to obtain the vaccine stock solution. The virus harvest solution is filtered in the following order: harvest solution → 10 μm filter → stock solution collection tank.

[0024] (5) Add an equal volume of freeze-dried stabilizer to the vaccine stock solution to obtain a semi-finished product.

[0025] (6) The obtained vaccine semi-finished product is packaged into vials at a volume of 0.6 ml / bottle, and the finished product is obtained after freeze-drying.

[0026] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0027] Example 1

[0028] Cell culture and mumps virus culture using a 5L basket bioreactor (recorded as batch 202201)

[0029] 1. Steps

[0030] 1.1 Pretreatment of 80 g of flake carrier (culture volume 5 L, so flake carrier concentration is 16 g / L)

[0031] 1.1 Prepare a 5L basket bioreactor, sterilize at 121℃ for 15min, add 5L MEM medium containing 10% newborn calf serum for pre-culture.

[0032] 1.2 Set the culture parameters of the bioreactor to pH 7.2, DO 50%, rotation speed 40 rpm, and temperature 37.0 °C. After the bioreactor parameters stabilize, inoculate KMB-17 cells at a density of 25 × 10 4 / mL.

[0033] 1.3 Cell culture

[0034] 1.3 Take samples and count the cells 30 minutes after entering the bioreactor. Change the rotation speed to 50 rpm after 24 hours of culture. After 48 hours of culture, use 10% NBS MEM at 5 L / d for perfusion culture until 96 hours. After 96 hours, use 0% NBS MEM at 10 L / d for perfusion culture until 120 hours. Monitor cell metabolism every day.

[0035] 1.4 Virus culture

[0036] 1.4 After 120h of cultivation, the culture medium in the bioreactor was replaced with 4L virus maintenance solution, each 1L virus maintenance solution contained 6.6% NaHCO340mL, 3% glutamine 20mL and MEM culture medium 940mL. After the parameters were stabilized (pH 7.8, DO50%, speed 50rpm, temperature 37.0°C), 1L virus maintenance solution containing virus seed was added and continued to be cultivated for 10 days (mumps virus F genotype SP-A strain virus seed, virus seed titer 6.25, MOI is 0.03). Samples were taken every day to detect the titer, and the virus culture was completed on the 10th day.

[0037] Results: The 202201 batch of cells were inoculated into the reactor and the cells were sampled and observed to be in good condition. After 30 minutes of inoculation, the cells were sampled and counted. The number of free cells in the supernatant was 2×10 4 / mL, that is, the cell adhesion rate was 92%. After culturing for 24 hours, the supernatant sampled and no free cells were found. The results are shown in Table 1. The maximum number of cells after 96 hours of cell growth was 41.2×10 8 .

[0038] Table 1: Growth of cells from batch 202201

[0039]

[0040] Comparative Example 1 is recorded as batch 202202

[0041] The other methods are exactly the same as those in Example 1, except that the MOI of the mumps virus F genotype SP-A strain is 0.02.

[0042] Results: The 202202 batch of cells were inoculated into the reactor and the cells were sampled and observed to be in good condition. After 30 minutes of entering the tank, the samples were taken for observation and counting. There were no free cells in the supernatant, that is, the cell adhesion rate was 100%. The daily grape consumption and total cell volume were calculated based on the cell metabolism data. The results are shown in Table 2. When the cells grew for 120 hours, the cell volume was 41.17×10 8 .

[0043] Table 2: Growth of cells from batch 202202

[0044]

[0045] Comparative Example 2 is recorded as batch 202203

[0046] The other methods are exactly the same as those in Example 1, except that the MOI of the mumps virus F genotype SP-A strain is 0.01.

[0047] Results: The 202203 batch of cells were inoculated into the fermenter and the cells were sampled and observed to be in good condition. After 30 minutes of inoculation, the cells were sampled and counted. The free cells in the supernatant were 3×10 4 / mL, that is, the cell adhesion rate was 88%. After 24 hours of culture, the supernatant sampled and no free cells were found. The results are shown in Table 3; the maximum number of cells after 96 hours of cell growth was 42×10 8 .

[0048] Table 3: Growth of cells from batch 202203

[0049]

[0050] The titer of the mumps virus solution obtained in Example 1, Comparative Example 1 and Comparative Example 2 was measured, and the results were as follows: Figure 1 shown.

[0051] The titers of the mumps virus harvest fluid obtained by inoculating the virus at three different MOIs were all high. The highest titer of the harvest fluid was 7.5IgCCID at an MOI of 0.03. 50 / mL; MOI was 0.02, and the highest titer of the harvested fluid was 7.625IgCCID 50 / mL; MOI was 0.01, and the highest titer of the harvested fluid was 7.5IgCCID 50 / mL. The highest titer of the harvest fluid obtained by the cell factory was 7.125IgCCID 50 / mL. Compared with the use of reactor-scale culture of human diploid cells to prepare F genotype mumps live attenuated vaccine, it has obvious advantages in the preparation of harvest fluid. The subsequent steps are unchanged.

[0052] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A method for preparing a live attenuated mumps vaccine of genotype F by culturing human diploid cells on a large scale, characterized in that: The steps include: (1) Human diploid KMB-17 cells were inoculated into a 5L basket bioreactor for cell culture; (2) inoculating mumps virus into the 5 L basket bioreactor for virus culture; (3) Preparation of harvest fluid; (4) Preparation of vaccine stock solution; (5) Preparation of vaccine semi-finished products; (6) Preparation of finished vaccine products; The seeding density of the human diploid KMB-17 cells in step (1) is 2-3×10 5 / mL; the cell culture time in step (1) is 4 to 6 days; the pH of the cell culture is 7.2±0.2; The inoculation MOI of the mumps virus strain in step (2) is 0.01-0.03; The titer of the mumps virus strain in step (2) is 5.5-6.5; the mumps virus strain is the mumps virus F genotype SP-A strain.

2. The method according to claim 1, characterized in that At the end of the cell culture in step (1), the cell count is 3.5-4.5×10 9 indivual.

3. The method according to claim 1, characterized in that: The virus culture time in step (2) is 4 to 7 days; the pH of the virus culture is 7.8±0.

2.

4. The method according to claim 1, characterized in that: After the virus culture in step (2) is completed, the supernatant is collected as the virus harvest fluid.

5. The method according to claim 1, characterized in that The virus harvested liquid in step (3) is filtered to remove cell debris to obtain the vaccine stock solution.

6. The method according to claim 1, characterized in that In step (5), an equal amount of lyophilization protective agent is added to the vaccine stock solution and mixed to obtain the vaccine semi-finished product.

7. The method according to claim 1, characterized in that The finished product of the vaccine semi-finished product obtained by subpackaging and freeze-drying is the finished product of the F genotype mumps live attenuated vaccine.

Citation Information

Patent Citations

  • F-genetype parotitis attenuated virus strain and use thereof

    CN101215552A

  • F-gene type attenuated live mumps vaccine and preparation method and application thereof

    CN102018956A

  • Method for preparing live attenuated rubella vaccine in human diploid cells by using basket-type bioreactor

    CN102743749A

  • Method for preparing genotype F mumps attenuated live vaccine

    CN103751772A

  • Diploid cell adaptive method of F genotype mumps viral strain MHM-19

    CN103756976A